These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1326 related articles for article (PubMed ID: 9520411)

  • 61. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells.
    Takeuchi T; Tsuboi T; Arai M; Togari A
    Biochem Pharmacol; 2001 Mar; 61(5):579-86. PubMed ID: 11239501
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.
    Hakeda Y; Kobayashi Y; Yamaguchi K; Yasuda H; Tsuda E; Higashio K; Miyata T; Kumegawa M
    Biochem Biophys Res Commun; 1998 Oct; 251(3):796-801. PubMed ID: 9790989
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
    Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
    J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
    Huang L; Xu J; Wood DJ; Zheng MH
    Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
    Ikeda T; Utsuyama M; Hirokawa K
    J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast.
    Akatsu T; Murakami T; Nishikawa M; Ono K; Shinomiya N; Tsuda E; Mochizuki S; Yamaguchi K; Kinosaki M; Higashio K; Yamamoto M; Motoyoshi K; Nagata N
    Biochem Biophys Res Commun; 1998 Sep; 250(2):229-34. PubMed ID: 9753612
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
    J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
    Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
    Shin MM; Kim YH; Kim SN; Kim GS; Baek JH
    Exp Mol Med; 2003 Jun; 35(3):167-74. PubMed ID: 12858015
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE; Bonnelye E
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Osteoclast differentiation factor in human osteosarcoma cell line.
    Kinpara K; Mogi M; Kuzushima M; Togari A
    J Immunoassay; 2000 Nov; 21(4):327-40. PubMed ID: 11071251
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
    Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
    Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
    J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells.
    Kanzawa M; Sugimoto T; Kanatani M; Chihara K
    Eur J Endocrinol; 2000 Jun; 142(6):661-4. PubMed ID: 10822231
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis.
    Yamagishi T; Otsuka E; Hagiwara H
    Endocrinology; 2001 Aug; 142(8):3632-7. PubMed ID: 11459812
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PTH differentially regulates expression of RANKL and OPG.
    Huang JC; Sakata T; Pfleger LL; Bencsik M; Halloran BP; Bikle DD; Nissenson RA
    J Bone Miner Res; 2004 Feb; 19(2):235-44. PubMed ID: 14969393
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts.
    Tada T; Jimi E; Okamoto M; Ozeki S; Okabe K
    Int J Cancer; 2005 Aug; 116(2):253-62. PubMed ID: 15800904
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 67.